Rousell R H
Department of Clinical Research, Cutter Laboratories, Miles Pharmaceutical, Berkeley, California 94701.
J Infect. 1987 Jul;15 Suppl 1:59-65. doi: 10.1016/s0163-4453(87)92502-3.
This is a review of the work leading to the generalized use of intravenous immunoglobulins (IVIgG) in the treatment of idiopathic thrombocytopenic purpura. Much of the work performed using a reduced and alkylated IVIgG is discussed. Finally, preliminary data on the results being achieved with a new non-modified IVIgG in idiopathic thrombocytopenic purpura (ITP) is dealt with in two studies involving a total of 42 patients.
这是一篇关于静脉注射免疫球蛋白（IVIgG）在特发性血小板减少性紫癜治疗中广泛应用的相关研究工作的综述。文中讨论了许多使用经还原和烷基化处理的IVIgG所开展的研究。最后，在两项涉及总共42例患者的研究中，探讨了一种新型未修饰IVIgG用于特发性血小板减少性紫癜（ITP）治疗所取得的初步数据。
